BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29845261)

  • 1. Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF‑κB signaling pathway.
    Zhao X; Wang X
    Mol Med Rep; 2018 Jul; 18(1):705-714. PubMed ID: 29845261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of candesartan on angiotensin II-induced renal vasoconstriction in rats and mice.
    Ruan X; Purdy KE; Oliverio MI; Coffman TM; Arendshorst WJ
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S202-7. PubMed ID: 9892164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candesartan inhibits LPS-induced expression increase of toll-like receptor 4 and downstream inflammatory factors likely via angiotensin II type 1 receptor independent pathway in human renal tubular epithelial cells.
    Zhao LQ; Huang JL; Yu Y; Lu Y; Fu LJ; Wang JL; Wang YD; Yu C
    Sheng Li Xue Bao; 2013 Dec; 65(6):623-30. PubMed ID: 24343720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candesartan ameliorates acute myocardial infarction in rats through inducible nitric oxide synthase, nuclear factor‑κB, monocyte chemoattractant protein‑1, activator protein‑1 and restoration of heat shock protein 72.
    Lin X; Wu M; Liu B; Wang J; Guan G; Ma A; Zhang Y
    Mol Med Rep; 2015 Dec; 12(6):8193-200. PubMed ID: 26499133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic NF-κB blockade improves renal angiotensin II type 1 receptor functions and reduces blood pressure in Zucker diabetic rats.
    Luo H; Wang X; Wang J; Chen C; Wang N; Xu Z; Chen S; Zeng C
    Cardiovasc Diabetol; 2015 Jun; 14():76. PubMed ID: 26055622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade.
    Chen S; Ge Y; Si J; Rifai A; Dworkin LD; Gong R
    Kidney Int; 2008 Nov; 74(9):1128-38. PubMed ID: 18650791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
    Gabor A; Leenen FH
    Hypertension; 2013 May; 61(5):1083-90. PubMed ID: 23509081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
    Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
    Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
    Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
    Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway.
    Fan F; Tian C; Tao L; Wu H; Liu Z; Shen C; Jiang G; Lu Y
    Biomed Pharmacother; 2016 Oct; 83():704-711. PubMed ID: 27470571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of biphasic effect on Na/K-ATPase activity by angiotensin II involves defective angiotensin type 1 receptor-nitric oxide signaling.
    Banday AA; Lokhandwala MF
    Hypertension; 2008 Dec; 52(6):1099-105. PubMed ID: 18955661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candesartan and insulin reduce renal sympathetic nerve activity in hypertensive type 1 diabetic rats.
    Takimoto C; Kumagai H; Osaka M; Sakata K; Onami T; Kamayachi T; Iigaya K; Hayashi K; Saruta T; Itoh H
    Hypertens Res; 2008 Oct; 31(10):1941-51. PubMed ID: 19015602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth.
    Fujita M; Hayashi I; Yamashina S; Fukamizu A; Itoman M; Majima M
    Carcinogenesis; 2005 Feb; 26(2):271-9. PubMed ID: 15637093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of angiotensin II type 1 receptor on pathological remodeling and dysfunction in obstructed bladder.
    Aikawa K; Sakai T; Ishibashi K; Shiomi H; Sagawa K; Kumagai S; Kataoka M; Akaihata H; Yamaguchi O
    Int J Urol; 2012 May; 19(5):457-64. PubMed ID: 22320898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candesartan ameliorates arsenic-induced hypertensive vascular remodeling by regularizing angiotensin II and TGF-beta signaling in rats.
    Khuman MW; Harikumar SK; Sadam A; Kesavan M; Susanth VS; Parida S; Singh KP; Sarkar SN
    Toxicology; 2016 Dec; 374():29-41. PubMed ID: 27889505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candesartan restored cardiac Hsp72 expression and tolerance against reperfusion injury in hereditary insulin-resistant rats.
    Taniguchi Y; Takahashi N; Fukui A; Nagano-Torigoe Y; Thuc LC; Teshima Y; Shinohara T; Wakisaka O; Ooie T; Murozono Y; Yufu K; Nakagawa M; Hara M; Yoshimatsu H; Saikawa T
    Cardiovasc Res; 2011 Dec; 92(3):439-48. PubMed ID: 21952935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer.
    Okazaki M; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Tajima H; Ninomiya I; Fujimura T; Ohta T
    Cancer Lett; 2014 Dec; 355(1):46-53. PubMed ID: 25224569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
    Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
    J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II.
    Chen K; Mehta JL; Li D; Joseph L; Joseph J
    Circ Res; 2004 Dec; 95(12):1167-73. PubMed ID: 15539634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candesartan, an angiotensin II type 1 receptor antagonist, inhibits pathological retinal neovascularization by downregulating VEGF receptor-2 expression.
    Nakamura S; Tsuruma K; Shimazawa M; Hara H
    Eur J Pharmacol; 2012 Jun; 685(1-3):8-14. PubMed ID: 22543084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.